INTRODUCTION: Despite recent advances in treatment, lung cancer remains the leading cause of cancer-related mortality in the United States. Therefore, there is a strong need for developing clinical trials in lung cancer therapeutics. Only a small fraction of patients with lung cancer are enrolled in clinical trials. It is critical to understand the barriers to participation in lung cancer clinical trials. METHODS: We reviewed the outpatient charts of consecutive patients with non-small cell lung cancer who presented for initial evaluation or consultation for further therapeutic management to the thoracic medical oncology group at the Alvin J. Siteman Cancer Center between January 1, 2006, and December 31, 2006. Available and appropriate clinical trials specific to the histologic subtype and stage were presented to the patients routinely, and reasons for nonenrollment were documented. We collected information on age, gender, ethnicity, histology, stage, performance status (PS), and insurance status. RESULTS: During the study period, 263 patients with non-small cell lung cancer were identified for the study. After initial screening, 183 patients had clinical trials available, which were appropriate for their diagnosis and stage of disease. One hundred one patients (55.2%) were ineligible for enrollment in a clinical trial. The most common reasons for ineligibility were poor PS (18%), need for emergent radiation (12%), lack of adequate staging information (6%), and comorbid conditions (4.9%). Despite being eligible for participation, 57 patients (31.1%) did not enroll in a clinical trial. Patient refusal accounted for 8.7%. The problems with transportation and distance from the medical center were reasons given for nonparticipation by 7.1%. Eleven patients (6%) did not participate in a clinical trial because of insurance issues. Ultimately, 25 patients (13.7%) were enrolled in a clinical trial. CONCLUSIONS: Poor PS, the need for emergent radiation, and patient refusal were the most common reasons for not participating in a clinical trial.
INTRODUCTION: Despite recent advances in treatment, lung cancer remains the leading cause of cancer-related mortality in the United States. Therefore, there is a strong need for developing clinical trials in lung cancer therapeutics. Only a small fraction of patients with lung cancer are enrolled in clinical trials. It is critical to understand the barriers to participation in lung cancer clinical trials. METHODS: We reviewed the outpatient charts of consecutive patients with non-small cell lung cancer who presented for initial evaluation or consultation for further therapeutic management to the thoracic medical oncology group at the Alvin J. Siteman Cancer Center between January 1, 2006, and December 31, 2006. Available and appropriate clinical trials specific to the histologic subtype and stage were presented to the patients routinely, and reasons for nonenrollment were documented. We collected information on age, gender, ethnicity, histology, stage, performance status (PS), and insurance status. RESULTS: During the study period, 263 patients with non-small cell lung cancer were identified for the study. After initial screening, 183 patients had clinical trials available, which were appropriate for their diagnosis and stage of disease. One hundred one patients (55.2%) were ineligible for enrollment in a clinical trial. The most common reasons for ineligibility were poor PS (18%), need for emergent radiation (12%), lack of adequate staging information (6%), and comorbid conditions (4.9%). Despite being eligible for participation, 57 patients (31.1%) did not enroll in a clinical trial. Patient refusal accounted for 8.7%. The problems with transportation and distance from the medical center were reasons given for nonparticipation by 7.1%. Eleven patients (6%) did not participate in a clinical trial because of insurance issues. Ultimately, 25 patients (13.7%) were enrolled in a clinical trial. CONCLUSIONS: Poor PS, the need for emergent radiation, and patient refusal were the most common reasons for not participating in a clinical trial.
Authors: Ricki Carroll; Jules Antigua; Darren Taichman; Harold Palevsky; Paul Forfia; Steven Kawut; Scott D Halpern Journal: Clin Trials Date: 2012-03-02 Impact factor: 2.486
Authors: Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber Journal: J Thorac Oncol Date: 2017-08-09 Impact factor: 15.609
Authors: Chi-Fu Jeffrey Yang; Matthew G Hartwig; Thomas A D'Amico; Mark F Berry Journal: J Thorac Cardiovasc Surg Date: 2015-09-05 Impact factor: 5.209
Authors: Rachel Jimenez; Baohui Zhang; Steven Joffe; Matthew Nilsson; Lorna Rivera; Jan Mutchler; Christopher Lathan; M Elizabeth Paulk; Holly G Prigerson Journal: J Palliat Med Date: 2013-02-05 Impact factor: 2.947
Authors: K M Islam; Samuel T Opoku; Bettye A Apenteng; Ann Fetrick; June Ryan; M Copur; Addison Tolentino; Irfan Vaziri; Apar K Ganti Journal: J Cancer Educ Date: 2014-12 Impact factor: 2.037
Authors: Luis E Gonzalez; Steven K Sutton; Christie Pratt; Matthew Gilbertson; Scott Antonia; Gwendolyn P Quinn Journal: J Cancer Educ Date: 2013-09 Impact factor: 2.037
Authors: Arti Hurria; William Dale; Margaret Mooney; Julia H Rowland; Karla V Ballman; Harvey J Cohen; Hyman B Muss; Richard L Schilsky; Betty Ferrell; Martine Extermann; Kenneth E Schmader; Supriya G Mohile Journal: J Clin Oncol Date: 2014-08-20 Impact factor: 44.544